A phase 1 study of Seclidemstat in patients with late stage triple negative breast cancer (TNBC), HER2-/ER+ breast cancer, and ovarian cancer

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Jan 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Seclidemstat (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Ovarian cancer; Triple negative breast cancer
Focus Adverse reactions

15 Jan 2019 According to a Salarius Pharmaceuticals website, the company is planning to initiate this phase 1 study, patients with late stage triple negative breast cancer, HER2-/ER+ breast cancer, and ovarian cancer. This study is sponsored by the Huntsman Cancer Institute.
15 Jan 2019 New trial record
04 Jan 2019 According to a Flex Pharma media release, the company expects to start a clinical study in breast and ovarian cancer in 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com